Department of Pharmacy, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, People's Republic of China.
School of Pharmacy, Xi'an Jiaotong University, Xi'an, Shaanxi, People's Republic of China.
Drug Des Devel Ther. 2023 Jan 24;17:191-207. doi: 10.2147/DDDT.S390274. eCollection 2023.
As the first-line drug to treat ulcerative colitis (UC), long-term use of glucocorticoids (GCs) produces severe toxic and side effects. Local administration as enema can increase the local GCs concentrations and reduce systemic exposure to high oral doses by directly delivering GCs to the inflammation site in the distal colorectum. However, UC patients are often accompanied by diarrhea, leading to the short colonic residence time of GCs and failure to exert their function fully.
A kind of mucoadhesive nanoparticles (NPs) loading different dexamethasone derivatives (DDs) were developed, which could attach to the positively charged inflammatory colonic mucosa through electrostatic adsorption after administered by enema, thereby improving the local concentration and achieving effective targeted therapy for UC.
Two DDs, dexamethasone hemisuccinate and dexamethasone phosphate, were synthesized. In NPs preparation, The core PEI-DDs NPs were built by the electrostatic adsorption of DDs and the cationic polymer polyethyleneimine (PEI). Then, the natural polyanionic polysaccharide sodium alginate (SA) was electronically coated around NPs to construct the final SA-PEI-DDs NPs, followed by the in vitro stability and release tests, in vitro and in vivo colonic mucosal adhesion tests. In the in vivo anti-UC test, the experimental colitis mice were induced by 2,4,6-trinitrobenzenesulfonic acid. The body weight and disease activity index changes were measured, and the myeloperoxidase activity, pro-inflammatory cytokines concentration, and hematoxylin and eosin staining were also investigated to evaluate the therapeutic effect of NPs.
The structures of two DDs were demonstrated by H-NMR and MS. Both NPs were negatively charged and achieved high loading efficiency of DDs, while their particle sizes were significantly different. NPs showed good stability and sustained release properties in the simulated colonic environment. Moreover, the negative charge on the of NPs surface made them easier to adhere to the positively charged inflammatory colonic mucosa, thereby enhancing the enrichment and retention of DDS in the colitis site. Furthermore, the NPs exhibited better therapeutic effects than free Dex on the experimental colitis mice induced by TNBS through the enema rectal.
These results indicated the mucoadhesive NPs as a kind of novel nano-enema showed great potential to achieve efficient treatment on UC.
作为治疗溃疡性结肠炎(UC)的一线药物,长期使用糖皮质激素(GCs)会产生严重的毒性和副作用。局部灌肠给药可以增加局部 GCs 浓度,并通过将 GCs 直接递送至远端结肠的炎症部位来减少全身暴露于高口服剂量。然而,UC 患者常伴有腹泻,导致 GCs 在结肠中的驻留时间较短,无法充分发挥其功能。
开发了一种载不同地塞米松衍生物(DDs)的粘膜粘附纳米颗粒(NPs),通过灌肠给药后,通过静电吸附附着在带正电荷的炎症性结肠黏膜上,从而提高局部浓度,实现 UC 的有效靶向治疗。
合成了两种 DDs,琥珀酸地塞米松和地塞米松磷酸酯。在 NPs 的制备中,通过 DDs 和阳离子聚合物聚乙烯亚胺(PEI)的静电吸附构建核心 PEI-DDs NPs。然后,将天然带负电荷的多糖海藻酸钠(SA)电子包裹在 NPs 周围,构建最终的 SA-PEI-DDs NPs,随后进行体外稳定性和释放试验、体外和体内结肠粘膜粘附试验。在体内抗 UC 试验中,通过 2,4,6-三硝基苯磺酸诱导实验性结肠炎小鼠。测量体重和疾病活动指数的变化,并研究髓过氧化物酶活性、促炎细胞因子浓度和苏木精和伊红染色,以评估 NPs 的治疗效果。
通过 H-NMR 和 MS 证明了两种 DDs 的结构。两种 NPs 均带负电荷,实现了 DDs 的高载药效率,但其粒径有明显差异。NPs 在模拟结肠环境中表现出良好的稳定性和持续释放性能。此外,NPs 表面的负电荷使其更容易附着在带正电荷的炎症性结肠黏膜上,从而增强了 DDS 在结肠炎部位的富集和保留。此外,通过 TNBS 直肠内给药,与游离 Dex 相比,NPs 对实验性结肠炎小鼠具有更好的治疗效果。
这些结果表明,粘膜粘附 NPs 作为一种新型的纳米灌肠剂,在治疗 UC 方面具有很大的潜力。